Stéphane Bancel, Endpoints JPM 2020 (Jeff Rumans)
Moderna eyes $500M secondary offering on upbeat coronavirus vaccine update — almost ready for the clinic
Among the army of biotechs that threw themselves into the gold rush for 2019-nCoV vaccines or therapies, Moderna emerged as one of the most legitimate …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
